HPR32 Assessing the Health Outcomes and Additional Budget Impact of PD-(L)1 Inhibitors in the Early Stages of Cancer Treatment in Greece
Abstract
Authors
N Yfantopoulos P Naoum A Skroumpelos A Karokis R. Aguiar-Ibáñez K Athanasakis D Sönmez